» Articles » PMID: 26860705

"Any Fool Can Make a Rule and Any Fool Will Mind It"

Overview
Journal BMC Med
Publisher Biomed Central
Specialty General Medicine
Date 2016 Feb 11
PMID 26860705
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

In principle, accurate guideline recommendations should lead to optimal management based on a secure diagnosis. However, current IPF diagnostic guidelines do not meet the needs of a major sub-group (possibly the majority) of patients with idiopathic pulmonary fibrosis (IPF). A great many IPF patients have HRCT appearances of "possible UIP". A surgical biopsy is very often impracticable due to age, disease severity, co-morbidities or patient refusal. A guideline-based diagnosis cannot be made in these patients, although the diagnosis is often obvious. Inflexible diagnostic criteria, although essential for treatment trials, must necessarily be structured around an inflexible diagnostic algorithm. With this approach, non-standardised information (i.e. not available in all patients) must be omitted, including observed disease behaviour prior to and on treatment, findings on bronchoalveolar lavage, likelihoods in relation to age and a wealth of ancillary clinical information. However, when a diagnosis cannot be made using guideline criteria, a probable or highly probable "working diagnosis" of IPF can and should be made in most IPF patients by means of clinical reasoning, integrating all available non-standardised information.

Citing Articles

Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives.

Cottin V, Martinez F, Smith V, Walsh S Eur Respir Rev. 2024; 31(165).

PMID: 38743511 PMC: 9724802. DOI: 10.1183/16000617.0003-2022.


Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease.

Berger K, Kaner R Life (Basel). 2023; 13(3).

PMID: 36983755 PMC: 10055741. DOI: 10.3390/life13030599.


Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a Analysis.

Molina-Molina M, Kreuter M, Cottin V, Corte T, Gilberg F, Kirchgaessler K Front Med (Lausanne). 2022; 9:897102.

PMID: 35783648 PMC: 9247211. DOI: 10.3389/fmed.2022.897102.


Survival analysis in lung cancer patients with interstitial lung disease.

Alomaish H, Ung Y, Wang S, Tyrrell P, Zahra S, Oikonomou A PLoS One. 2021; 16(9):e0255375.

PMID: 34492020 PMC: 8423282. DOI: 10.1371/journal.pone.0255375.


A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease.

Ryerson C, Corte T, Myers J, Walsh S, Guler S Eur Respir J. 2021; 58(6).

PMID: 34140296 PMC: 8674517. DOI: 10.1183/13993003.00276-2021.


References
1.
Raghu G, Collard H, Egan J, Martinez F, Behr J, Brown K . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6):788-824. PMC: 5450933. DOI: 10.1164/rccm.2009-040GL. View

2.
Selman M, King T, Pardo A . Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001; 134(2):136-51. DOI: 10.7326/0003-4819-134-2-200101160-00015. View

3.
Lettieri C, Veerappan G, Helman D, Mulligan C, Shorr A . Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest. 2005; 127(5):1600-5. DOI: 10.1378/chest.127.5.1600. View

4.
Greenhalgh T, Howick J, Maskrey N . Evidence based medicine: a movement in crisis?. BMJ. 2014; 348:g3725. PMC: 4056639. DOI: 10.1136/bmj.g3725. View

5.
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen H . High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005; 353(21):2229-42. DOI: 10.1056/NEJMoa042976. View